nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Death—Docetaxel—head and neck cancer	0.0238	0.0982	CcSEcCtD
Carfilzomib—PSMB5—hair follicle—head and neck cancer	0.0164	0.0704	CbGeAlD
Carfilzomib—Peripheral motor neuropathy—Docetaxel—head and neck cancer	0.015	0.062	CcSEcCtD
Carfilzomib—PSMB1—hair follicle—head and neck cancer	0.0144	0.0615	CbGeAlD
Carfilzomib—PSMB2—hair follicle—head and neck cancer	0.014	0.06	CbGeAlD
Carfilzomib—PSMB8—parotid gland—head and neck cancer	0.0102	0.0435	CbGeAlD
Carfilzomib—PSMB10—lymphoid tissue—head and neck cancer	0.0102	0.0435	CbGeAlD
Carfilzomib—PSMB8—saliva-secreting gland—head and neck cancer	0.00974	0.0417	CbGeAlD
Carfilzomib—PSMB10—thyroid gland—head and neck cancer	0.00922	0.0395	CbGeAlD
Carfilzomib—PSMB5—parotid gland—head and neck cancer	0.00898	0.0385	CbGeAlD
Carfilzomib—PSMB5—saliva-secreting gland—head and neck cancer	0.0086	0.0368	CbGeAlD
Carfilzomib—Multi-organ failure—Docetaxel—head and neck cancer	0.00843	0.0347	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00833	0.0343	CcSEcCtD
Carfilzomib—PSMB8—Vinorelbine—Vinblastine—head and neck cancer	0.00828	0.539	CbGdCrCtD
Carfilzomib—PSMB10—head—head and neck cancer	0.00818	0.035	CbGeAlD
Carfilzomib—PSMB1—parotid gland—head and neck cancer	0.00785	0.0336	CbGeAlD
Carfilzomib—Neuritis—Vinblastine—head and neck cancer	0.00777	0.032	CcSEcCtD
Carfilzomib—PSMB2—parotid gland—head and neck cancer	0.00766	0.0328	CbGeAlD
Carfilzomib—PSMB1—saliva-secreting gland—head and neck cancer	0.00752	0.0322	CbGeAlD
Carfilzomib—PSMB8—trachea—head and neck cancer	0.00751	0.0322	CbGeAlD
Carfilzomib—PSMB2—saliva-secreting gland—head and neck cancer	0.00734	0.0314	CbGeAlD
Carfilzomib—PSMB8—Vincristine—Vinblastine—head and neck cancer	0.00708	0.461	CbGdCrCtD
Carfilzomib—PSMB2—connective tissue—head and neck cancer	0.00674	0.0289	CbGeAlD
Carfilzomib—PSMB5—trachea—head and neck cancer	0.00664	0.0284	CbGeAlD
Carfilzomib—PSMB8—thyroid gland—head and neck cancer	0.00594	0.0255	CbGeAlD
Carfilzomib—PSMB1—trachea—head and neck cancer	0.0058	0.0248	CbGeAlD
Carfilzomib—PSMB10—lymph node—head and neck cancer	0.00573	0.0245	CbGeAlD
Carfilzomib—PSMB2—trachea—head and neck cancer	0.00566	0.0242	CbGeAlD
Carfilzomib—Lymphopenia—Docetaxel—head and neck cancer	0.00537	0.0221	CcSEcCtD
Carfilzomib—PSMB5—thyroid gland—head and neck cancer	0.00525	0.0225	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—head and neck cancer	0.00505	0.0216	CbGeAlD
Carfilzomib—PSMB2—lymphoid tissue—head and neck cancer	0.00493	0.0211	CbGeAlD
Carfilzomib—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00474	0.0195	CcSEcCtD
Carfilzomib—PSMB1—thyroid gland—head and neck cancer	0.00459	0.0197	CbGeAlD
Carfilzomib—PSMB2—thyroid gland—head and neck cancer	0.00448	0.0192	CbGeAlD
Carfilzomib—Hepatic failure—Hydroxyurea—head and neck cancer	0.00427	0.0176	CcSEcCtD
Carfilzomib—Renal failure acute—Hydroxyurea—head and neck cancer	0.00416	0.0171	CcSEcCtD
Carfilzomib—PSMB1—head—head and neck cancer	0.00407	0.0174	CbGeAlD
Carfilzomib—PSMB2—head—head and neck cancer	0.00397	0.017	CbGeAlD
Carfilzomib—PSMB8—lymph node—head and neck cancer	0.00369	0.0158	CbGeAlD
Carfilzomib—Neuritis—Docetaxel—head and neck cancer	0.00368	0.0152	CcSEcCtD
Carfilzomib—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.0036	0.0148	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Docetaxel—head and neck cancer	0.00342	0.0141	CcSEcCtD
Carfilzomib—Sepsis—Fluorouracil—head and neck cancer	0.0033	0.0136	CcSEcCtD
Carfilzomib—PSMB5—lymph node—head and neck cancer	0.00326	0.014	CbGeAlD
Carfilzomib—Acute coronary syndrome—Vinblastine—head and neck cancer	0.0032	0.0132	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00318	0.0131	CcSEcCtD
Carfilzomib—Neutropenia—Hydroxyurea—head and neck cancer	0.0031	0.0128	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.0029	0.0119	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vinblastine—head and neck cancer	0.0029	0.0119	CcSEcCtD
Carfilzomib—PSMB1—lymph node—head and neck cancer	0.00285	0.0122	CbGeAlD
Carfilzomib—PSMB2—lymph node—head and neck cancer	0.00278	0.0119	CbGeAlD
Carfilzomib—Cardiac arrest—Fluorouracil—head and neck cancer	0.00263	0.0108	CcSEcCtD
Carfilzomib—Sepsis—Docetaxel—head and neck cancer	0.00238	0.00982	CcSEcCtD
Carfilzomib—Chills—Hydroxyurea—head and neck cancer	0.00238	0.00981	CcSEcCtD
Carfilzomib—Anaemia—Vinblastine—head and neck cancer	0.00234	0.00965	CcSEcCtD
Carfilzomib—Leukopenia—Vinblastine—head and neck cancer	0.00227	0.00935	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00222	0.00914	CcSEcCtD
Carfilzomib—Hepatic failure—Docetaxel—head and neck cancer	0.00222	0.00914	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.0022	0.00906	CcSEcCtD
Carfilzomib—Hypertension—Vinblastine—head and neck cancer	0.00219	0.00901	CcSEcCtD
Carfilzomib—Pneumonia—Fluorouracil—head and neck cancer	0.00214	0.00882	CcSEcCtD
Carfilzomib—Anaemia—Hydroxyurea—head and neck cancer	0.00214	0.0088	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.0021	0.00865	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00209	0.0086	CcSEcCtD
Carfilzomib—Leukopenia—Hydroxyurea—head and neck cancer	0.00207	0.00852	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vinblastine—head and neck cancer	0.00203	0.00834	CcSEcCtD
Carfilzomib—Hyponatraemia—Docetaxel—head and neck cancer	0.002	0.00825	CcSEcCtD
Carfilzomib—Pain in extremity—Docetaxel—head and neck cancer	0.00199	0.00821	CcSEcCtD
Carfilzomib—Anorexia—Vinblastine—head and neck cancer	0.00197	0.00812	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fluorouracil—head and neck cancer	0.0019	0.00783	CcSEcCtD
Carfilzomib—Infection—Hydroxyurea—head and neck cancer	0.00187	0.00772	CcSEcCtD
Carfilzomib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00185	0.00761	CcSEcCtD
Carfilzomib—Anorexia—Hydroxyurea—head and neck cancer	0.0018	0.00741	CcSEcCtD
Carfilzomib—Decreased appetite—Vinblastine—head and neck cancer	0.0018	0.00741	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.0018	0.0074	CcSEcCtD
Carfilzomib—Constipation—Vinblastine—head and neck cancer	0.00177	0.00729	CcSEcCtD
Carfilzomib—Pain—Vinblastine—head and neck cancer	0.00177	0.00729	CcSEcCtD
Carfilzomib—Dyspnoea—Hydroxyurea—head and neck cancer	0.00168	0.00693	CcSEcCtD
Carfilzomib—Decreased appetite—Hydroxyurea—head and neck cancer	0.00164	0.00675	CcSEcCtD
Carfilzomib—Fatigue—Hydroxyurea—head and neck cancer	0.00163	0.0067	CcSEcCtD
Carfilzomib—Pain—Hydroxyurea—head and neck cancer	0.00161	0.00665	CcSEcCtD
Carfilzomib—Constipation—Hydroxyurea—head and neck cancer	0.00161	0.00665	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—head and neck cancer	0.00161	0.00664	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—head and neck cancer	0.00155	0.00637	CcSEcCtD
Carfilzomib—Anaemia—Fluorouracil—head and neck cancer	0.00154	0.00633	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00152	0.00624	CcSEcCtD
Carfilzomib—Renal failure—Docetaxel—head and neck cancer	0.00151	0.00622	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00151	0.0062	CcSEcCtD
Carfilzomib—Body temperature increased—Hydroxyurea—head and neck cancer	0.00149	0.00614	CcSEcCtD
Carfilzomib—Leukopenia—Fluorouracil—head and neck cancer	0.00149	0.00613	CcSEcCtD
Carfilzomib—Asthenia—Vinblastine—head and neck cancer	0.00148	0.00611	CcSEcCtD
Carfilzomib—Diarrhoea—Vinblastine—head and neck cancer	0.00142	0.00583	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—head and neck cancer	0.00137	0.00565	CcSEcCtD
Carfilzomib—Dizziness—Vinblastine—head and neck cancer	0.00137	0.00563	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—head and neck cancer	0.00136	0.0056	CcSEcCtD
Carfilzomib—Asthenia—Hydroxyurea—head and neck cancer	0.00135	0.00558	CcSEcCtD
Carfilzomib—Infection—Fluorouracil—head and neck cancer	0.00135	0.00556	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00133	0.00548	CcSEcCtD
Carfilzomib—Vomiting—Vinblastine—head and neck cancer	0.00132	0.00542	CcSEcCtD
Carfilzomib—Headache—Vinblastine—head and neck cancer	0.0013	0.00534	CcSEcCtD
Carfilzomib—Anorexia—Fluorouracil—head and neck cancer	0.00129	0.00533	CcSEcCtD
Carfilzomib—Diarrhoea—Hydroxyurea—head and neck cancer	0.00129	0.00532	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—head and neck cancer	0.00128	0.00527	CcSEcCtD
Carfilzomib—Dizziness—Hydroxyurea—head and neck cancer	0.00125	0.00514	CcSEcCtD
Carfilzomib—Chills—Docetaxel—head and neck cancer	0.00124	0.0051	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00124	0.0051	CcSEcCtD
Carfilzomib—Nausea—Vinblastine—head and neck cancer	0.00123	0.00506	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—head and neck cancer	0.00123	0.00506	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—head and neck cancer	0.00121	0.00499	CcSEcCtD
Carfilzomib—Vomiting—Hydroxyurea—head and neck cancer	0.0012	0.00494	CcSEcCtD
Carfilzomib—Headache—Hydroxyurea—head and neck cancer	0.00118	0.00487	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—head and neck cancer	0.00118	0.00486	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—head and neck cancer	0.00116	0.00478	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—head and neck cancer	0.00116	0.00478	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—head and neck cancer	0.00115	0.00476	CcSEcCtD
Carfilzomib—Nausea—Hydroxyurea—head and neck cancer	0.00112	0.00462	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—head and neck cancer	0.00111	0.00457	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—head and neck cancer	0.00108	0.00443	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—head and neck cancer	0.00107	0.00442	CcSEcCtD
Carfilzomib—Cough—Docetaxel—head and neck cancer	0.00105	0.00432	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—head and neck cancer	0.00104	0.00427	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—head and neck cancer	0.00102	0.00421	CcSEcCtD
Carfilzomib—ABCB1—epithelium—head and neck cancer	0.000978	0.00419	CbGeAlD
Carfilzomib—Infection—Docetaxel—head and neck cancer	0.000974	0.00401	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—head and neck cancer	0.00096	0.00395	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—head and neck cancer	0.000934	0.00385	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—head and neck cancer	0.000929	0.00383	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—head and neck cancer	0.000898	0.0037	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000893	0.00368	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—head and neck cancer	0.000887	0.00365	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—head and neck cancer	0.000874	0.0036	CcSEcCtD
Carfilzomib—ABCB1—trachea—head and neck cancer	0.000865	0.0037	CbGeAlD
Carfilzomib—Vomiting—Fluorouracil—head and neck cancer	0.000864	0.00356	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—head and neck cancer	0.000852	0.00351	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—head and neck cancer	0.000851	0.0035	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—head and neck cancer	0.000845	0.00348	CcSEcCtD
Carfilzomib—Pain—Docetaxel—head and neck cancer	0.000838	0.00345	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—head and neck cancer	0.000838	0.00345	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—head and neck cancer	0.000807	0.00332	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—head and neck cancer	0.000775	0.00319	CcSEcCtD
Carfilzomib—ABCB1—lymphoid tissue—head and neck cancer	0.000753	0.00323	CbGeAlD
Carfilzomib—Asthenia—Docetaxel—head and neck cancer	0.000703	0.0029	CcSEcCtD
Carfilzomib—ABCB1—thyroid gland—head and neck cancer	0.000684	0.00293	CbGeAlD
Carfilzomib—Diarrhoea—Docetaxel—head and neck cancer	0.000671	0.00276	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—head and neck cancer	0.000648	0.00267	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—head and neck cancer	0.000623	0.00257	CcSEcCtD
Carfilzomib—Headache—Docetaxel—head and neck cancer	0.000614	0.00253	CcSEcCtD
Carfilzomib—ABCB1—head—head and neck cancer	0.000607	0.0026	CbGeAlD
Carfilzomib—Nausea—Docetaxel—head and neck cancer	0.000582	0.0024	CcSEcCtD
Carfilzomib—ABCB1—lymph node—head and neck cancer	0.000425	0.00182	CbGeAlD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000112	0.000221	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PTEN—head and neck cancer	0.000112	0.00022	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PTEN—head and neck cancer	0.000111	0.000219	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—head and neck cancer	0.000111	0.000219	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—BCL2—head and neck cancer	0.000111	0.000218	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—BCL2—head and neck cancer	0.000111	0.000218	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—BCL2—head and neck cancer	0.000111	0.000218	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—BCL2—head and neck cancer	0.000109	0.000215	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—STAT3—head and neck cancer	0.000108	0.000213	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—STAT3—head and neck cancer	0.000108	0.000212	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTGS2—head and neck cancer	0.000108	0.000212	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTGS2—head and neck cancer	0.000107	0.000211	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—PIK3CA—head and neck cancer	0.000107	0.00021	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—PIK3CA—head and neck cancer	0.000107	0.00021	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—PIK3CA—head and neck cancer	0.000107	0.00021	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—PIK3CA—head and neck cancer	0.000105	0.000207	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MAPK3—head and neck cancer	0.000104	0.000204	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MAPK3—head and neck cancer	0.000103	0.000203	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MAPK3—head and neck cancer	0.000103	0.000203	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MAPK3—head and neck cancer	0.000103	0.000202	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	0.000102	0.0002	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—STAT3—head and neck cancer	0.0001	0.000197	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—STAT3—head and neck cancer	9.97e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—head and neck cancer	9.89e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—head and neck cancer	9.89e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—head and neck cancer	9.89e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MAPK1—head and neck cancer	9.86e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—head and neck cancer	9.86e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MAPK1—head and neck cancer	9.81e-05	0.000193	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—head and neck cancer	9.81e-05	0.000193	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—head and neck cancer	9.77e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—head and neck cancer	9.77e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—head and neck cancer	9.77e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—head and neck cancer	9.75e-05	0.000192	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTGS2—head and neck cancer	9.73e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTGS2—head and neck cancer	9.73e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTGS2—head and neck cancer	9.73e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—head and neck cancer	9.63e-05	0.000189	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	9.61e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTGS2—head and neck cancer	9.59e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MAPK3—head and neck cancer	9.57e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MAPK3—head and neck cancer	9.52e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTEN—head and neck cancer	9.38e-05	0.000185	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTEN—head and neck cancer	9.33e-05	0.000184	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PTEN—head and neck cancer	9.19e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PTEN—head and neck cancer	9.19e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PTEN—head and neck cancer	9.19e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOTCH1—head and neck cancer	9.18e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOTCH1—head and neck cancer	9.18e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOTCH1—head and neck cancer	9.18e-05	0.000181	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	9.14e-05	0.00018	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	9.14e-05	0.00018	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MAPK1—head and neck cancer	9.1e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—head and neck cancer	9.1e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PTEN—head and neck cancer	9.06e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MAPK1—head and neck cancer	9.06e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—head and neck cancer	9.06e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOTCH1—head and neck cancer	9.05e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—head and neck cancer	8.73e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—head and neck cancer	8.73e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—head and neck cancer	8.73e-05	0.000172	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NAT2—head and neck cancer	8.61e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—head and neck cancer	8.61e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—PIK3CA—head and neck cancer	8.56e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—PIK3CA—head and neck cancer	8.52e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTEN—head and neck cancer	8.49e-05	0.000167	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTEN—head and neck cancer	8.49e-05	0.000167	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTEN—head and neck cancer	8.49e-05	0.000167	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTEN—head and neck cancer	8.37e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—head and neck cancer	8.33e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—head and neck cancer	8.29e-05	0.000163	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—head and neck cancer	8.22e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—head and neck cancer	8.22e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—head and neck cancer	8.22e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—head and neck cancer	8.15e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—head and neck cancer	8.15e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—head and neck cancer	8.15e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—head and neck cancer	8.12e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—head and neck cancer	8.11e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—head and neck cancer	8.09e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—head and neck cancer	8.04e-05	0.000158	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	7.93e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—head and neck cancer	7.92e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—head and neck cancer	7.9e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—head and neck cancer	7.88e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—head and neck cancer	7.86e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK3—head and neck cancer	7.85e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK3—head and neck cancer	7.85e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK3—head and neck cancer	7.85e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTEN—head and neck cancer	7.84e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MAPK3—head and neck cancer	7.81e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MAPK3—head and neck cancer	7.81e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MAPK3—head and neck cancer	7.81e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTEN—head and neck cancer	7.8e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK3—head and neck cancer	7.74e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MAPK3—head and neck cancer	7.7e-05	0.000151	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	7.67e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—head and neck cancer	7.59e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—head and neck cancer	7.59e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—head and neck cancer	7.59e-05	0.000149	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DPYD—head and neck cancer	7.55e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—head and neck cancer	7.48e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK1—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK1—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK1—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—head and neck cancer	7.47e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK1—head and neck cancer	7.37e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—head and neck cancer	7.37e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—head and neck cancer	7.31e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—head and neck cancer	7.27e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—head and neck cancer	7.25e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—head and neck cancer	7.25e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—head and neck cancer	7.25e-05	0.000143	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—YAP1—head and neck cancer	7.17e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—head and neck cancer	7.15e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—head and neck cancer	7.11e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—head and neck cancer	7.11e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—head and neck cancer	7.11e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—head and neck cancer	7.08e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—head and neck cancer	7.05e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—head and neck cancer	7.01e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—head and neck cancer	7.01e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—head and neck cancer	6.99e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—head and neck cancer	6.98e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—head and neck cancer	6.96e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—head and neck cancer	6.95e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—head and neck cancer	6.92e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK1—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK1—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK1—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—head and neck cancer	6.9e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK1—head and neck cancer	6.8e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—head and neck cancer	6.8e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—head and neck cancer	6.7e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—head and neck cancer	6.67e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—head and neck cancer	6.62e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—head and neck cancer	6.58e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—head and neck cancer	6.48e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—head and neck cancer	6.48e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—head and neck cancer	6.48e-05	0.000128	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	6.48e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—head and neck cancer	6.45e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—head and neck cancer	6.42e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—head and neck cancer	6.39e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK1—head and neck cancer	6.38e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—head and neck cancer	6.37e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK1—head and neck cancer	6.35e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—head and neck cancer	6.34e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—head and neck cancer	6.32e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—head and neck cancer	6.32e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—head and neck cancer	6.32e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—head and neck cancer	6.23e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—head and neck cancer	6.16e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—head and neck cancer	6.16e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—head and neck cancer	6.16e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—head and neck cancer	6.07e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—head and neck cancer	6e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—head and neck cancer	6e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—head and neck cancer	6e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—head and neck cancer	5.99e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—head and neck cancer	5.99e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—head and neck cancer	5.99e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—head and neck cancer	5.94e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—head and neck cancer	5.94e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—head and neck cancer	5.94e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—head and neck cancer	5.92e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—head and neck cancer	5.9e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—head and neck cancer	5.86e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—head and neck cancer	5.54e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—head and neck cancer	5.54e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—head and neck cancer	5.54e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—head and neck cancer	5.53e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—head and neck cancer	5.51e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—head and neck cancer	5.46e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—head and neck cancer	5.4e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—head and neck cancer	5.38e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—head and neck cancer	5.37e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—head and neck cancer	5.37e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—head and neck cancer	5.37e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—head and neck cancer	5.35e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—head and neck cancer	5.33e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—head and neck cancer	5.32e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—head and neck cancer	5.32e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—head and neck cancer	5.32e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—head and neck cancer	5.3e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—head and neck cancer	5.3e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—head and neck cancer	5.3e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—head and neck cancer	5.29e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—head and neck cancer	5.27e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—head and neck cancer	5.27e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—head and neck cancer	5.27e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—head and neck cancer	5.24e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—head and neck cancer	5.22e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—head and neck cancer	5.19e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—head and neck cancer	5.12e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—head and neck cancer	5.09e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—head and neck cancer	5.08e-05	9.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—head and neck cancer	5.08e-05	9.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—head and neck cancer	5.08e-05	9.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—head and neck cancer	5.01e-05	9.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—head and neck cancer	5.01e-05	9.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—head and neck cancer	5.01e-05	9.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—head and neck cancer	5.01e-05	9.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—head and neck cancer	4.94e-05	9.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—head and neck cancer	4.89e-05	9.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—head and neck cancer	4.89e-05	9.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—head and neck cancer	4.89e-05	9.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK1—head and neck cancer	4.83e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK1—head and neck cancer	4.83e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK1—head and neck cancer	4.83e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—head and neck cancer	4.83e-05	9.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—head and neck cancer	4.83e-05	9.5e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—head and neck cancer	4.83e-05	9.5e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—head and neck cancer	4.82e-05	9.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK1—head and neck cancer	4.76e-05	9.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—head and neck cancer	4.76e-05	9.37e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—head and neck cancer	4.52e-05	8.89e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—head and neck cancer	4.5e-05	8.85e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—head and neck cancer	4.3e-05	8.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—head and neck cancer	4.25e-05	8.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—head and neck cancer	4.19e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—head and neck cancer	4.19e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—head and neck cancer	4.19e-05	8.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—head and neck cancer	4.13e-05	8.13e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—head and neck cancer	4.1e-05	8.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—head and neck cancer	4.1e-05	8.06e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—head and neck cancer	4.1e-05	8.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPX1—head and neck cancer	4.07e-05	8.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—head and neck cancer	4.06e-05	7.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—head and neck cancer	4.06e-05	7.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—head and neck cancer	4.06e-05	7.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—head and neck cancer	4.04e-05	7.94e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—head and neck cancer	4.03e-05	7.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—head and neck cancer	4e-05	7.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—head and neck cancer	3.88e-05	7.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—head and neck cancer	3.88e-05	7.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—head and neck cancer	3.88e-05	7.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—head and neck cancer	3.82e-05	7.52e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—head and neck cancer	3.43e-05	6.74e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—head and neck cancer	3.43e-05	6.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—head and neck cancer	3.43e-05	6.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—head and neck cancer	3.38e-05	6.64e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—head and neck cancer	2.4e-05	4.72e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—head and neck cancer	2.09e-05	4.11e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.48e-05	2.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—head and neck cancer	1.21e-05	2.37e-05	CbGpPWpGaD
